FGEN 250516 5.00P(FGEN250516P5000) Stock Price Today

0.00
0.000.00%

15min DelayTrading Apr 24 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jenna Ragan

Apr 3 06:34

$FibroGen (FGEN.US)$

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Teddy123

Mar 28 20:25

Financial Analysis

$FibroGen (FGEN.US)$
This Phase 1 data publication represents a positive development for FibroGen's oncology pipeline diversification strategy. For a micro-cap company ($33.5M market cap), advancing a potential first-in-class asset with demonstrated clinical activity addresses a critical need for pipeline momentum.
The decision to advance FG-3246 into Phase 2 by mid-2025 signals management confidence in the asset's potential, while the planned combination study with enzalutamid...

Teddy123

Mar 28 20:24

Oncology analysis

$FibroGen (FGEN.US)$
The publication of FG-3246's Phase 1 data in the Journal of Clinical Oncology represents a meaningful clinical milestone for FibroGen's oncology pipeline. The data shows 20% objective response rate with 7.5 months median duration of response and 80% disease control rate in a particularly challenging population - patients who received a median of 5 prior therapies.
What's noteworthy is FG-3246's novel mechanism as a CD46-targeting antibody-drug conjugate, rep...

Teddy123

Mar 28 19:07

FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology

$FibroGen (FGEN.US)$
Breakthrough Cancer Drug FG-3246 Achieves 80% Disease Control Rate in Hard-to-Treat Prostate Cancer

Jaguar8

Mar 28 19:01

NEWS

$FibroGen (FGEN.US)$
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
Friday, 28th March at 7:00 am
• FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancer
• Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC expected by mid-2025
SAN F...

FGEN250516P5000

News

Comments